Radiotherapy and short-term androgen deprivation for localized prostate cancer.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  New England Journal of Medicine

• Publication date

  2011-07-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMoa1012348PMID 21751904
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Metabolic complications of androgen deprivation therapy for prostate cancer.

  2013cited by this paper
• Randomized, double-blinded, placebo-controlled crossover trial of treating erectile dysfunction with sildenafil after radiotherapy and short-term androgen deprivation therapy: results of RTOG 0215.

  2011cited by this paper
• Risk-based management of prostate cancer.

  2011cited by this paper
• The 2010 NCCN clinical practice guidelines in oncology on prostate cancer.

  2010cited by this paper
• Duration of Androgen Suppression in the Treatment of Prostate Cancer

  2010cited by this paper
• Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09.

  2010cited by this paper
• Long‐term follow‐up of 3‐month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial

  2010cited by this paper
• Duration of androgen suppression in the treatment of prostate cancer.

  2009cited by this paper
• Metabolic complications of androgen deprivation therapy for prostate cancer.

  2009cited by this paper
• Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer.

  2008cited by this paper
• Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.

  2008cited by this paper
• Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.

  2008cited by this paper
• Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer.

  2008cited by this paper
• Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.

  2008cited by this paper
• Prostate cancer. Clinical practice guidelines in oncology.

  2007cited by this paper
• Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial.

  2007cited by this paper
• Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.

  2006cited by this paper
• Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

  2006cited by this paper
• Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.

  2005cited by this paper
• Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

  2005cited by this paper
• 10-year outcome for men with localized prostate cancer treated with external radiation therapy: results of a cohort study.

  2004cited by this paper
• Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer

  2004cited by this paper
• Clinical investigation: prostateRadical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer

  2004cited by this paper
• The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry.

  2004cited by this paper
• Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.

  2002cited by this paper
• Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate.

  2001cited by this paper
• Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials.

  2000cited by this paper
• Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience.

  2000cited by this paper
• Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study.

  2000cited by this paper
• Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience.

  2000cited by this paper
• A Proportional Hazards Model for the Subdistribution of a Competing Risk

  1999cited by this paper
• Long-term survival after radiotherapy alone: radiation therapy oncology group prostate cancer trials.

  1999cited by this paper
• Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.

  1997cited by this paper
• Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)

  1995cited by this paper
• Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group.

  1995cited by this paper
• Hormonal treatment of advanced disease: some newer aspects.

  1994cited by this paper
• Applications of crude incidence curves.

  1992cited by this paper
• An assessment of clinically useful measures of the consequences of treatment.

  1988cited by this paper
• Development of the sexual adjustment questionnaire.

  1986cited by this paper
• The randomization and stratification of patients to clinical trials.

  1974cited by this paper
• Regression Models and Life-Tables

  1972cited by this paper
• Evaluation of survival data and two new rank order statistics arising in its consideration.

  1966cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Kinetics of prostate volume reduction under hormonal treatment: Timing and impact on external beam radiotherapy - A PRISMA-Compliant systematic review.

  2026cites this paper
• Fecal incontinence after prostate cancer irradiation: a systematic literature review.

  2026cites this paper
• Cardiovascular risks in men with prostate cancer: a pragmatic, clinician-oriented review of risk stratification and management strategies.

  2025cites this paper
• Localized high-risk prostate cancer harbors an androgen receptor activity–low subpopulation susceptible to HER2 inhibition

  2025cites this paper
• Risk-adapted durations of hormone therapy combined with radiotherapy for prostate cancer

  2025cites this paper
• Assessing the effects of prostate cancer therapies on cardiovascular health

  2025cites this paper
• Assessing Algorithmic Fairness With a Multimodal Artificial Intelligence Model in Men of African and Non-African Origin on NRG Oncology Prostate Cancer Phase III Trials

  2025cites this paper
• Metabolomics of Prostate Cancer and Clinical Profiles Following Radiotherapy: Need for a Precision Phylometabolomics Approach

  2025cites this paper
• Functional outcomes and complications following salvage radical prostatectomy for post radiotherapy recurrent prostate cancer: A meta-analysis.

  2025cites this paper
• Salvage brachytherapy for local recurrence of prostate cancer. Evaluation of technique and dose fractionation, impact of early diagnosis, and its effect on survival. A multicenter retrospective observational study: RESPRO.

  2025cites this paper
• Time to Benefit of Androgen Deprivation Therapy in Patients With Localized Prostate Cancer Undergoing Radiotherapy

  2025influential citation
• Optimizing Radiation Therapy for Localized Prostate Cancer: Exploring Synergies With Androgen Deprivation Therapy and Novel Systemic Agents.

  2025cites this paper
• Neoadjuvant Therapies for Prostate Cancer–Current Paradigms and Future Directions

  2025influential citation
• Emulating an Existing Trial of Treatments for Prostate Cancer Using Real-World Data: Challenges and lessons learned.

  2025cites this paper
• LHRH Antagonists Restore Serum Testosterone Faster Than LHRH Agonists in Prostate Cancer Patients After Radiotherapy

  2025cites this paper
• On the Origin of Treatment Paradigms.

  2025cites this paper
• The Benefit of Short-Term Androgen Deprivation Therapy with Radiotherapy for Intermediate-Risk Prostate Cancer.

  2025cites this paper
• PACE-B: Where does this position SBRT as an option for localized prostate cancer?

  2025cites this paper
• Overall Survival in Men 80 and Older With Intermediate-Risk Prostate Cancer Who are Treated With Dose-Escalated Radiation and Androgen Deprivation Therapy Versus Dose-Escalated Radiation Alone: A National Cancer Database Analysis

  2025cites this paper
• Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1

  2024cites this paper
• N-terminal domain of androgen receptor is a major therapeutic barrier and potential pharmacological target for treating castration resistant prostate cancer: a comprehensive review

  2024cites this paper
• Delayed definitive management of localized prostate cancer: what do we know?

  2024cites this paper
• A phase II trial of apalutamide for intermediate‐risk prostate cancer and molecular correlates

  2024cites this paper
• Impact of neoadjuvant relugolix on patient-reported sexual function and bother

  2024cites this paper
• Elective Pelvic Lymph Node Radiation Therapy and the Risk of Death in Patients With Unfavorable-Risk Prostate Cancer: A Postrandomization Analysis

  2024cites this paper
• Overview of Radiation Therapy in the Management of Localized and Metastatic Prostate Cancer

  2024cites this paper
• Systematic review and recommendations for re-irradiation for intraprostatic radiorecurrent prostate cancer after definitive radiation therapy

  2024cites this paper
• Effects of Androgen Deprivation Therapy Duration on Health-Related Quality of Life, Physical Activity, Anxiety and Depression Levels in Patients with Intermediate- and High-Risk Prostate Cancer

  2024cites this paper
• Impact of neoadjuvant androgen deprivation therapy on toxicity in intensity-modulated radiation therapy for prostate cancer

  2024cites this paper
• The impact of neoadjuvant relugolix on multi-dimensional patient-reported fatigue

  2024cites this paper
• CACA guidelines for holistic integrative management of prostate cancer

  2024cites this paper
• The effect of dose‐escalation radiotherapy with simultaneous‐integrated‐boost on the use of short‐term androgen deprivation therapy in patients with intermediate risk prostate cancer

  2024influential citation
• Development of depression in patients using androgen deprivation therapy: A systemic review and meta‐analysis

  2024cites this paper
• Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials

  2024cites this paper
• Stimulating Soluble Guanylyl Cyclase with the Clinical Agonist Riociguat Restrains the Development and Progression of Castration-Resistant Prostate Cancer.

  2024cites this paper
• Tumor epitope spreading by a novel multivalent therapeutic cellular vaccine targeting cancer antigens to invariant NKT-triggered dendritic cells in situ

  2024cites this paper
• Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis

  2024influential citation
• Radiation Therapy Summary of the AUA/ASTRO Guideline on Clinically Localized Prostate Cancer.

  2024cites this paper
• Susceptibility to radiation adverse effects in veterans with Gulf War illness and healthy civilians

  2024cites this paper
• Understanding RBE and clinical outcome of prostate cancer therapy using particle irradiation: analysis of tumor control probability with mMKM.

  2024cites this paper
• Biochemical response to neoadjuvant androgen deprivation therapy before radiation therapy and the risk of death in patients with unfavorable‐risk prostate cancer: A secondary analysis of a randomized clinical trial

  2024cites this paper
• Recommandations françaises du comité de cancérologie de l’AFU – Actualisation 2024–2026 : cancer de la prostate – diagnostic et prise en charge de la maladie localisée

  2024cites this paper
• An Overview of Diagnosis to Survivorship of Prostate Cancer after Experiencing Radiotherapy

  2024cites this paper
• French AFU Cancer Committee Guidelines - Update 2024-2026: Prostate cancer - Diagnosis and management of localised disease.

  2024cites this paper
• Localized high-risk prostate cancer harbors an androgen receptor low subpopulation susceptible to HER2 inhibition

  2024cites this paper
• Luteinizing hormone-releasing hormone receptor agonists and antagonists in prostate cancer: effects on long-term survival and combined therapy with next-generation hormonal agents

  2024cites this paper
• Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed Prostate Cancer

  2024cites this paper
• Racial Disparity in Utilizing Genetic Testing for Personalized Care of Prostate Cancer

  2023cites this paper
• Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate

  2023cites this paper
• Association of PSA kinetics after testosterone recovery with subsequent recurrence: secondary analysis of a phase III randomized controlled trial

  2023cites this paper
• The Current Trend of Radiation Therapy for Patients with Localized Prostate Cancer

  2023cites this paper
• Re: Dose-escalated Radiotherapy Alone or in Combination with Short-term Androgen Deprivation for Intermediate-risk Prostate Cancer: Results of a Phase III Multi-institutional Trial.

  2023cites this paper
• Ablative radiotherapy improves survival but does not cure autochthonous mouse models of prostate and colorectal cancer

  2023cites this paper
• A Systematic Review of Patient Race, Ethnicity, Socioeconomic Status, and Educational Attainment in Prostate Cancer Treatment Randomised Trials—Is the Evidence Base Applicable to the General Patient Population?

  2023cites this paper
• Neoadjuvant versus Concurrent Androgen Deprivation Therapy in Localized Prostate Cancer Treated with Radiotherapy: A Systematic Review of the Literature

  2023cites this paper
• Racial disparity in the genomics of precision oncology of prostate cancer

  2023cites this paper
• Prediction of prostate tumour hypoxia using pre-treatment MRI-derived radiomics: preliminary findings

  2023cites this paper
• Prevalence, trends, and characteristics of trials investigating local therapy in contemporary phase 3 clinical cancer research

  2023cites this paper
• Risk of Short-Term Prostate-Specific Antigen Recurrence and Failure in Patients With Prostate Cancer

  2023cites this paper
• 15-year biochemical failure, metastasis, salvage therapy, and cancer-specific and overall survival rates in men treated with robotic radical prostatectomy for PSA-screen detected prostate cancer

  2023cites this paper
• The soluble guanylyl cyclase pathway is inhibited to evade androgen deprivation-induced senescence and enable progression to castration resistance

  2023cites this paper
• Outcomes after definitive radiation therapy for localized prostate cancer in a national health care delivery system

  2023cites this paper
• Node Oligorecurrence in Prostate Cancer: A Challenge

  2023cites this paper
• Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial.

  2023cites this paper
• Are high-risk prostate cancer patients being treated equally? The impact of PSA.

  2023cites this paper
• Multimodality Therapies for Localized Prostate Cancer

  2023cites this paper
• Intensity-modulated radiation therapy for intermediate-risk prostate cancer: does ADT still have an impact in the dose-escalated external beam radiation therapy era?

  2023cites this paper
• Genomic classifier performance in intermediate-risk prostate cancer: Results from NRG Oncology/RTOG 0126 randomized phase III trial.

  2023cites this paper
• Improved Multimodal Fusion for Small Datasets with Auxiliary Supervision

  2023cites this paper
• Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial

  2023cites this paper
• Eliciting men’s preferences for decision-making relative to treatments of localized prostate cancer with a good or moderate prognosis

  2023cites this paper
• Comparison of four-year toxicities and local control of ultra-hypofractionated vs moderate-hypofractionated image guided prostate radiation with HDR brachytherapy boost: A phase I-II single institution trial

  2023cites this paper
• Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer.

  2023cites this paper
• Mental health outcomes in a population-based cohort of patients with prostate cancer.

  2023cites this paper
• Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer.

  2023cites this paper
• Outcomes of salvage robot-assisted radical prostatectomy in patients who had primary focal versus whole-gland ablation: a multicentric study

  2023cites this paper
• Preoperative PI-RADS v2.1 Scoring System Improves Risk Classification in Patients Undergoing Radical Prostatectomy

  2023cites this paper
• Impact of sequencing of androgen receptor-signaling inhibition and radiotherapy in prostate cancer: importance of homologous recombination disruption

  2023cites this paper
• Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer

  2023cites this paper
• Review of Current Treatment Intensification Strategies for Prostate Cancer Patients

  2023cites this paper
• Les grands principes des traitements du cancer de prostate localisé

  2023cites this paper
• ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer.

  2023cites this paper
• Local versus systemic treatment intensification: what is the optimal strategy for localized prostate cancer?

  2022cites this paper
• Co-Inhibition of Androgen Receptor and PARP as a Novel Treatment Paradigm in Prostate Cancer—Where Are We Now?

  2022cites this paper
• Assessing the role of external beam radiation therapy in combination with brachytherapy versus brachytherapy alone for unfavorable intermediate-risk prostate cancer.

  2022cites this paper
• Trends in Androgen Deprivation Use in Men With Intermediate-Risk Prostate Cancer Who Underwent Radiation Therapy

  2022cites this paper
• Outcomes of Patients With Unfavorable Intermediate-Risk Prostate Cancer Treated With External-Beam Radiotherapy Versus Brachytherapy Alone.

  2022cites this paper
• Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis.

  2022cites this paper
• Personalization of Treatment Intensity for Intermediate-Risk Prostate Cancer.

  2022cites this paper
• Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology.

  2022cites this paper
• Re: Androgen deprivation therapy and radiotherapy in intermediate risk prostate cancer: A randomized phase III trial.

  2022cites this paper
• Clinical Case Debate: Immunotherapy Versus Alternative Therapies in the Neoadjuvant and Adjuvant Setting of Localized, High-Risk Prostate Cancer

  2022cites this paper
• A "scoping" review of prostate brachytherapy and immune responses.

  2022cites this paper
• Initial Quality of Life and Toxicity Analysis of a Randomized Phase 3 Study of Moderately Hypofractionated Radiation Therapy With or Without Androgen Suppression for Intermediate-Risk Adenocarcinoma of the Prostate: PCG GU003

  2022cites this paper
• Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT

  2022cites this paper
• French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Diagnosis and management of localised disease.

  2022cites this paper
• PARP inhibitors in metastatic prostate cancer: When, who, and how?

  2022cites this paper
• Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A systematic review and meta-analysis

  2022cites this paper
• Drivers of Radioresistance in Prostate Cancer

  2022cites this paper
• Androgen receptor splicing variant 7 (ARv7) promotes DNA damage response in prostate cancer cells

  2022cites this paper